These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 12232821)

  • 1. Mapping out the future in venous thromboembolism and acute coronary syndromes.
    Heit JA
    Semin Thromb Hemost; 2002 Aug; 28 Suppl 3():33-9. PubMed ID: 12232821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies for the treatment of acute venous thromboembolism.
    Prandoni P; Lensing AW; Pesavento R
    Semin Thromb Hemost; 2006 Nov; 32(8):787-92. PubMed ID: 17171591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants.
    DeLoughery TG
    Crit Care Clin; 2005 Jul; 21(3):497-512. PubMed ID: 15992670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Venous thromboembolism and cancer].
    Ferrari E; Benhamou M; Berkane N; Baudouy M
    Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1307-12. PubMed ID: 11794974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of recurrent venous thomboembolism--expanding the frontier.
    Prins MH; Marchiori A
    Thromb Haemost; 2002 Jan; 87(1):1-3. PubMed ID: 11848436
    [No Abstract]   [Full Text] [Related]  

  • 7. Thromboembolic diseases.
    Wakefield TW; Caprini J; Comerota AJ
    Curr Probl Surg; 2008 Dec; 45(12):844-99. PubMed ID: 18984095
    [No Abstract]   [Full Text] [Related]  

  • 8. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism.
    Motsch J; Walther A; Bock M; Böttiger BW
    Curr Opin Anaesthesiol; 2006 Feb; 19(1):52-8. PubMed ID: 16547433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
    Koscielny J; Kiesewetter H; Jörg I; Harenberg J
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting.
    Ennis RS
    J South Orthop Assoc; 2003; 12(1):10-7. PubMed ID: 12735619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
    Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
    Jochberger S; Mayr V; Luckner G; Fries DR; Mayr AJ; Friesenecker BE; Lorenz I; Hasibeder WR; Ulmer H; Schobersberger W; Dünser MW
    Crit Care; 2005 Oct; 9(5):R541-8. PubMed ID: 16277716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term management of patients after venous thromboembolism.
    Kearon C
    Circulation; 2004 Aug; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism in the pregnant woman.
    Phillips OP
    J Reprod Med; 2003 Nov; 48(11 Suppl):921-9. PubMed ID: 14686029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of pulmonary embolism and venous thrombosis prophylaxis.
    Wakefield TW; Proctor MC
    Semin Vasc Surg; 2000 Sep; 13(3):171-81. PubMed ID: 11005460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism and cancer: risks and outcomes.
    Lee AY; Levine MN
    Circulation; 2003 Jun; 107(23 Suppl 1):I17-21. PubMed ID: 12814981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.